Francesco Berlanda Scorza
Overview
Explore the profile of Francesco Berlanda Scorza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Massai L, Carducci M, Rovetini L, Paterson A, Whitcombe A, McGregor R, et al.
J Immunol Methods
. 2024 Dec;
536():113786.
PMID: 39643029
Exposure to Group A Streptococcus leads to a broad spectrum of disease and sequelae, as the bacterium employs a wide range of virulence factors to facilitate colonization of the host,...
2.
Carducci M, Massai L, Lari E, Semplici B, Grappi S, Maria N, et al.
Front Immunol
. 2024 Nov;
15:1443137.
PMID: 39539546
Typhoid and Paratyphoid fever cause a global health burden, especially for the children of Southern Asia. The impact of the disease is further exacerbated by the dramatic increase of antimicrobial...
3.
Di Benedetto R, Massai L, Wright M, Mancini F, Cleveland M, Rossi O, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519015
Alum is the most used vaccine adjuvant, due to its safety, low cost and adjuvanticity to various antigens. However, the mechanism of action of alum is complex and not yet...
4.
Carducci M, Massai L, Lari E, Semplici B, Aruta M, De Simone D, et al.
Front Immunol
. 2024 Oct;
15:1466869.
PMID: 39478859
Effective vaccines against Typhi, targeting the Vi capsular polysaccharide, have been developed and are being introduced into routine immunization in endemic countries. Vi conjugated vaccines are also being tested in...
5.
Leroux-Roels I, Maes C, Mancini F, Jacobs B, Sarakinou E, Alhatemi A, et al.
J Infect Dis
. 2024 Jun;
230(4):e971-e984.
PMID: 38853614
Background: We report data from stage 1 of an ongoing 2-staged, phase 1/2 randomized clinical trial with a 4-component generalized modules for membrane antigens-based vaccine against Shigella sonnei and Shigella...
6.
Bloom D, Pecetta S, Scorza F, Carfi A, Carleton B, Cipriano M, et al.
Sci Transl Med
. 2024 May;
16(745):eadm9183.
PMID: 38691620
As the world's population grows older, vaccination is becoming a key strategy for promoting healthy aging. Despite scientific progress in adult vaccine development, obstacles such as immunosenescence and vaccine hesitancy...
7.
Batani G, Vezzani G, Lashchuk S, Allaoui A, Cardamone D, Raso M, et al.
Front Immunol
. 2024 Apr;
15:1374293.
PMID: 38680489
Introduction: is the etiologic agent of a bacillary dysentery known as shigellosis, which causes millions of infections and thousands of deaths worldwide each year due to 's unique lifestyle within...
8.
Mancini F, Caradonna V, Alfini R, Aruta M, Vitali C, Gasperini G, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675229
Shigellosis is one of the leading causes of diarrheal disease in low- and middle-income countries, particularly in young children, and is more often associated with antimicrobial resistance. Therefore, a preventive...
9.
Nonne F, Molfetta M, Nappini R, La Guidara C, Di Benedetto R, Mfana S, et al.
Biology (Basel)
. 2024 Apr;
13(4).
PMID: 38666868
(Kp) is a Gram-negative bacterium, and a leading cause of neonatal sepsis in low- and middle-income countries, often associated with anti-microbial resistance. Two types of polysaccharides are expressed on the...
10.
Boero E, Carducci M, Keeley A, Scorza F, Iturriza-Gomara M, Moriel D, et al.
J Immunol Methods
. 2024 Mar;
528:113652.
PMID: 38458312
Streptococcus pyogenes, commonly referred to as Group A Streptococcus (Strep A), causes a spectrum of diseases, with the potential to progress into life-threatening illnesses and autoimmune complications. The escalating threat...